Johnson & Johnson COVID-19 vaccine not as effective as others

Fauci says the Johnson & Johnson COVID-19 vaccine will alleviate stress on the U.S. health care system
Mgn 1280x960 00923b00 Nyiyv

LINCOLN, Neb. (KLKN)- Johnson & Johnson have been working on a single-shot COVID-19 vaccine that they claim to be 66% effective in preventing moderate to severe disease in the global Phase 3 trial, 85% effective against severe disease, and 72% effective against moderate to severe disease in the United States.

Both the Pfizer/BioNTech and Moderna COVID-19 vaccines have been labeled 95% effective, giving people pause when it comes to Johnson & Johnson’s vaccine.

But Dr. Fauci says that their vaccine will be a way of alleviating stress on the health care system in America.

“If we can alleviate that, that is really important — not only with this candidate but the others that have already gotten the EUA,” Fauci, director of the National Institute of Allergy and Infectious Diseases, said during a call with CNN reporters on Friday morning.

Johnson & Johnson is supposed to apply for emergency use authorization of their vaccine next week, becoming the third company to ask for an EUA from the FDA.

SEE ALSO: Nebraska launches COVID-19 vaccine registration portal

Categories: Coronavirus, News, US & World